ABSTRACT
A serological survey of 2,430 archived serum samples collected between 1997 and 2012 was conducted to retrospectively determine the prevalence of Marburg virus in five African countries. Serum samples were screened for neutralizing antibodies in a pseudotype micro-neutralization assay and confirmed by enzyme-linked immunosorbent assay (ELISA). Surprisingly, a seroprevalence for Marburg virus of 7.5 and 6.3% was found in Cameroon and Ghana, respectively, suggesting the circulation of filoviruses or related viruses outside of known endemic areas that remain undetected by current surveillance efforts. However, due to the lack of validated assays and appropriate positive controls, these results must be considered preliminary.
Subject(s)
Antibodies, Viral/blood , Filoviridae/immunology , Marburg Virus Disease/blood , Marburg Virus Disease/epidemiology , Marburgvirus/immunology , Animals , Cameroon/epidemiology , Enzyme-Linked Immunosorbent Assay , Filoviridae/genetics , Filoviridae Infections/blood , Filoviridae Infections/epidemiology , Filoviridae Infections/virology , Ghana/epidemiology , Humans , Marburg Virus Disease/virology , Marburgvirus/genetics , Retrospective Studies , Seroepidemiologic StudiesABSTRACT
We conducted a serologic survey of 2,430 serum samples collected during 1997-2012 for various studies to determine the prevalence of the hemorrhagic fever virus Ebola virus (EBOV) in equatorial Africa. We screened serum samples for neutralizing antibodies by using a pseudotype microneutralization assay and a newly developed luciferase immunoprecipitation system assay. Specimens seroreactive for EBOV were confirmed by using an ELISA. Our results suggest a serologic prevalence of 2%-3.5% in the Republic of the Congo and the Democratic Republic of the Congo, which have reported outbreaks of infection with EBOV. In addition we detected a seroprevalence of 1.3% in southern Cameroon, which indicated a low risk for exposure in this region.
